J A Ledermann

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    Jonathan Ledermann
    University College London UCL Cancer Institute, UCL and UCL Hospitals Comprehensive Biomedical Research Centre, 90 Tottenham Court Rd, London W1T 4TJ, United Kingdom
    N Engl J Med 366:1382-92. 2012
  2. doi request reprint Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer
    J A Ledermann
    Department of Oncology, University College London, London, United Kingdom
    Int J Gynecol Cancer 18:53-8. 2008
  3. doi request reprint Targeted trials in ovarian cancer
    Jonathan A Ledermann
    UCL Cancer Institute, University College London, London W1T 4TJ, UK
    Gynecol Oncol 119:151-6. 2010
  4. doi request reprint Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer
    Jonathan A Ledermann
    UCL Hospitals, UCL Cancer Institute, London, United Kingdom
    Clin Cancer Res 16:4899-905. 2010
  5. doi request reprint Optimal treatment for relapsing ovarian cancer
    J A Ledermann
    UCL Cancer Institute, University College London, London, UK
    Ann Oncol 21:vii218-22. 2010
  6. ncbi request reprint How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Jonathan A Ledermann
    Department Oncology, University College London, London, UK
    Cancer Invest 22:2-10. 2004
  7. doi request reprint Primary chemotherapy: the future for the management of advanced ovarian cancer?
    Jonathan A Ledermann
    Cancer Research UK and UCL Cancer Centre, UCL Cancer Institute, University College London, London, United Kingdom
    Int J Gynecol Cancer 20:S17-9. 2010
  8. doi request reprint Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
    Jonathan A Ledermann
    UCL Cancer Institute, UCLH and UCL Biomedical Research Centre, University College London, London, United Kingdom
    Int J Gynecol Cancer 21:S9-11. 2011
  9. doi request reprint Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
    Jonathan A Ledermann
    MRC NCRI, UK
    Int J Gynecol Cancer 21:763-70. 2011
  10. doi request reprint Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
    Jonathan A Ledermann
    Cancer Research UK and University College London Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Rd, London W1T 4TJ
    J Clin Oncol 29:3798-804. 2011

Collaborators

Detail Information

Publications33

  1. doi request reprint Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    Jonathan Ledermann
    University College London UCL Cancer Institute, UCL and UCL Hospitals Comprehensive Biomedical Research Centre, 90 Tottenham Court Rd, London W1T 4TJ, United Kingdom
    N Engl J Med 366:1382-92. 2012
    ..Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations...
  2. doi request reprint Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer
    J A Ledermann
    Department of Oncology, University College London, London, United Kingdom
    Int J Gynecol Cancer 18:53-8. 2008
    ..Their different designs and results are reviewed, as well as some of the lessons that have been learned about HDC in solid tumors in the last decade...
  3. doi request reprint Targeted trials in ovarian cancer
    Jonathan A Ledermann
    UCL Cancer Institute, University College London, London W1T 4TJ, UK
    Gynecol Oncol 119:151-6. 2010
    ..We highlight some of the complex issues about sequencing, duration of therapy and selection of agents to aid the debate about the best use of molecular targeted agents in the treatment of ovarian cancer...
  4. doi request reprint Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer
    Jonathan A Ledermann
    UCL Hospitals, UCL Cancer Institute, London, United Kingdom
    Clin Cancer Res 16:4899-905. 2010
    ..Peripheral blood lymphocytes were sampled after drug administration to measure DNA interstrand cross-link formation and repair...
  5. doi request reprint Optimal treatment for relapsing ovarian cancer
    J A Ledermann
    UCL Cancer Institute, University College London, London, UK
    Ann Oncol 21:vii218-22. 2010
    ..In this review we discuss current practice in the treatment of relapsed ovarian cancer and highlight the most promising emerging therapeutics and strategies being employed in randomized clinical trials...
  6. ncbi request reprint How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Jonathan A Ledermann
    Department Oncology, University College London, London, UK
    Cancer Invest 22:2-10. 2004
    ..More studies are needed to explore other combinations of treatment in this group of women as the choice and timing of second-line therapy needs to take account of the benefits and toxicity of treatment...
  7. doi request reprint Primary chemotherapy: the future for the management of advanced ovarian cancer?
    Jonathan A Ledermann
    Cancer Research UK and UCL Cancer Centre, UCL Cancer Institute, University College London, London, United Kingdom
    Int J Gynecol Cancer 20:S17-9. 2010
    ..Furthermore, delayed surgery provides more knowledge about the biological behavior of the tumor, and this could be used to tailor treatment more effectively...
  8. doi request reprint Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
    Jonathan A Ledermann
    UCL Cancer Institute, UCLH and UCL Biomedical Research Centre, University College London, London, United Kingdom
    Int J Gynecol Cancer 21:S9-11. 2011
    ....
  9. doi request reprint Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
    Jonathan A Ledermann
    MRC NCRI, UK
    Int J Gynecol Cancer 21:763-70. 2011
    ..These areas were discussed at the 4th Ovarian Cancer Consensus Conference...
  10. doi request reprint Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
    Jonathan A Ledermann
    Cancer Research UK and University College London Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Rd, London W1T 4TJ
    J Clin Oncol 29:3798-804. 2011
    ..Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease...
  11. ncbi request reprint Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council
    M T Seymour
    Colorectal Cancer Working Party, United Kingdom Medical Research Council, London, United Kingdom
    J Clin Oncol 14:2280-8. 1996
    ..To determine the effects of interferon alpha-2a (IFN alpha) on the efficacy and toxicity of fluorouracil (FUra) and leucovorin (LV) in patients with advanced colorectal cancer...
  12. pmc Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
    F A Raja
    Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Road, London W1T 4TJ, UK
    Br J Cancer 105:884-9. 2011
    ..The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidence of single-agent activity in ovarian cancer with acceptable toxicity...
  13. pmc Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies
    D M Lane
    Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, UK
    Br J Cancer 70:521-5. 1994
    ..F(ab')2 fragments may provide a substantially enhanced method of delivering RIT...
  14. pmc The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies
    Y Olabiran
    Department of Oncology, University College London Medical School, UK
    Br J Cancer 69:247-52. 1994
    ....
  15. pmc Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer
    D Ornadel
    Department of Oncology, UCL Medical School, London, UK
    Br J Cancer 77:103-9. 1998
    ..The probable explanation for this distribution is that NY3D11 reacted with soluble NCAM or natural killer cells that possess the CD56 (NCAM) antigen...
  16. pmc Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy
    P Wynne
    Cancer Research UK Drug DNA Interactions Research Group, UCL, London, UK
    Br J Cancer 97:927-33. 2007
    ..85 rising to 71.23 following treatment. These data demonstrate increased repair of DNA interstrand crosslinks in ovarian tumour cells following platinum therapy which may contribute to clinical acquired resistance...
  17. ncbi request reprint Optimal first-line treatment in ovarian cancer
    F A Raja
    UCL Cancer Institute, Cancer Research UK and UCL Cancer Trials Centre, London, UK
    Ann Oncol 23:x118-27. 2012
    ..In this review, we discuss the existing treatments for ovarian cancer and highlight areas of recent progress...
  18. ncbi request reprint High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)
    J A Ledermann
    Department of Oncology, Royal Free and University College Medical School, UCL, London, UK
    Ann Oncol 12:693-9. 2001
    ..to determine the outcome of epithelial ovarian cancer in patients registered with the European Group for Blood and Marrow Transplantation (EBMT)...
  19. pmc Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study
    Allan Hackshaw
    Cancer Research, UK
    J R Soc Med 101:299-304. 2008
    ..To evaluate the specific components of setting up a simple multicentre clinical study four years after the new UK law on clinical trials was implemented in 2004...
  20. pmc Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer
    J A Ledermann
    Department of Oncology, University College London Medical School, Middlesex Hospital, UK
    Br J Cancer 68:119-21. 1993
    ..This study shows that the biodistribution of radiolabelled SWA11 in man differs from human tumour xenograft models and that the antibody in unsuitable for targeting therapy to SCLC in man...
  21. doi request reprint Primary tumour resection and survival in the palliative management of metastatic colorectal cancer
    A Bajwa
    Department of Surgery, University College London Hospitals, London, UK
    Eur J Surg Oncol 35:164-7. 2009
    ..To examine whether surgical resection of the primary tumour confers a survival benefit and to identify the predictive factors of outcome in patients presenting with asymptomatic metastatic colorectal cancer (CRC)...
  22. pmc Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy
    G M Boxer
    University Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, UK
    Br J Cancer 65:825-31. 1992
    ..Preoperative administration of radiolabelled antibody to CEA may be helpful in selecting patients with favourable localisation for radioimmunotherapy...
  23. ncbi request reprint Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial
    T S Maughan
    Department of Oncology, Velindre Hospital, Cardiff, UK
    Lancet 361:457-64. 2003
    ..Policies of UK clinicians regarding the duration of chemotherapy for patients with advanced colorectal cancer are not consistent. We aimed to compare effectiveness of continuous and intermittent chemotherapy in such patients...
  24. ncbi request reprint Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial
    T S Maughan
    Department of Oncology, Velindre Hospital, Cardiff, UK
    Lancet 359:1555-63. 2002
    ....
  25. pmc Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
    P Leonard
    Royal Free and University College Medical School, UCL, London, UK
    Br J Cancer 87:1216-20. 2002
    ..Grade 3-4 mucositis was not seen and severe alopecia affected only three patients. IrMdG is an active and well-tolerated regimen for both the first and second line treatment of advanced colorectal cancer...
  26. ncbi request reprint Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells
    Cheryl L L Chiang
    Department of Immunology and Molecular Pathology, Division of Infection and Immunity, UCL, Windeyer Building, 46 Cleveland Street, W1T 4JF, London, UK
    Cancer Immunol Immunother 55:1384-95. 2006
    ..In order to enhance their immunogenicity, ovarian tumor cells (SK-OV-3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl)...
  27. doi request reprint Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma
    Anjana A Kulkarni
    Department of Pathology and Cancer Institute, Cancer Institute, University College London, London, United Kingdom
    Clin Cancer Res 15:2417-25. 2009
    ..We tested the hypothesis that Cdc7 kinase, a core component of the licensing machinery, is predictive of clinical outcome and may constitute a novel therapeutic target in epithelial ovarian carcinoma...
  28. doi request reprint Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor
    Cheryl L L Chiang
    Division of Infection and Immunity, University College London, London, United Kingdom
    Clin Cancer Res 14:4898-907. 2008
    ..In this study, we examine whether ovarian epithelial cells (SK-OV-3) exposed to hypochlorous acid can stimulate T cells from patients with ovarian epithelial cancer that recognize common tumor antigens as well as autologous tumor...
  29. ncbi request reprint DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma
    Anjana A Kulkarni
    Department of Pathology, Royal Free and University College Medical School, London, United Kingdom
    Clin Cancer Res 13:6153-61. 2007
    ..We used multiparameter analyses of these cell cycle regulatory proteins to investigate their role in the progression of epithelial ovarian carcinoma (EOC)...
  30. ncbi request reprint Management of platinum-sensitive recurrent ovarian cancer
    Jacobus Pfisterer
    Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitatsklinikum Schleswig Holstein, Germany
    Semin Oncol 33:S12-6. 2006
    ..The choice of treatment needs to take into account the increase in side effects when using combination chemotherapy compared with carboplatin monotherapy, and the different toxicities of the two combination regimens...
  31. ncbi request reprint Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT
    Volker Möbus
    Department of Obstetrics and Gynecology, Städtisches Klinikum, Gotenstrasse 6 8, D 65929 Frankfurt, Germany
    J Clin Oncol 25:4187-93. 2007
    ..A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome...
  32. ncbi request reprint Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer
    Lia van Zuylen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Clin Cancer Res 10:1949-55. 2004
    ....
  33. ncbi request reprint Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
    Matthew T Seymour
    University of Leeds and corrected Cookridge Hospital, Leeds, UK
    Lancet 370:143-52. 2007
    ..We compared sequential and combination chemotherapy strategies in patients with unpretreated advanced or metastatic colorectal cancer, who were regarded as not potentially curable irrespective of response...